Literature DB >> 12922098

Comparative analysis of effects of cytokine gene adjuvants on DNA vaccination against Mycobacterium tuberculosis heat shock protein 65.

Kyoung Min Baek1, Sung-Youl Ko, Mira Lee, Joong-Seok Lee, Jae-Ouk Kim, Hyun-Jeong Ko, Jae-Woo Lee, Sang-Hoon Lee, Sang-Nae Cho, Chang-Yuil Kang.   

Abstract

DNA-based vaccines generate potent cellular immunity as well as humoral immunity. It seems evident that cytokines play a crucial role in generation of effector T cell subsets and in determining the magnitude of the response by DNA vaccines. In this study, we compared the effects of several TH1 cytokine genes as adjuvant in DNA vaccination using mycobacterial Hsp65 as a model antigen. Our results demonstrated that although the overall immune response to Hsp65 was enhanced by co-injection of Hsp65 DNA with cytokine genes, each cytokine gene was shown to affect different immune response elements. Co-injection of Hsp65 DNA with IL-12 or GM-CSF led to an increase in IFN-gamma production and represented potent protections against Mycobacterium tuberculosis challenge, while that with Eta-1, IL-12 or IL-18 gene led to an elevated IgG2a/IgG1 ratio. Interestingly, co-administration of Flt3L gene was shown to enhance the Ag-specific CTL response. These results show that the direction and magnitude of immune response in DNA vaccination against Hsp65 of M. tuberculosis could be modulated in different ways by co-injection of an appropriate cytokine gene as adjuvant.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922098     DOI: 10.1016/s0264-410x(03)00378-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B.

Authors:  Hyun-Jeong Ko; Sung-Youl Ko; Yeon-Jeong Kim; Eun-Gae Lee; Sang-Nae Cho; Chang-Yuil Kang
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine.

Authors:  Avi-Hai Hovav; Yolanta Fishman; Herve Bercovier
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates.

Authors:  Peter T Loudon; Eric J Yager; Debbie T Lynch; Amithi Narendran; Cristy Stagnar; Anthony M Franchini; James T Fuller; Phil A White; Julia Nyuandi; Clayton A Wiley; Michael Murphey-Corb; Deborah H Fuller
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

4.  Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis.

Authors:  James A Triccas; Elena Shklovskaya; Joanne Spratt; Anthony A Ryan; Umaimainthan Palendira; Barbara Fazekas de St Groth; Warwick J Britton
Journal:  Infect Immun       Date:  2007-08-27       Impact factor: 3.441

5.  Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis.

Authors:  Masaji Okada; Yoko Kita; Toshihiro Nakajima; Noriko Kanamaru; Satomi Hashimoto; Tetsuji Nagasawa; Yasufumi Kaneda; Shigeto Yoshida; Yasuko Nishida; Hitoshi Nakatani; Kyoko Takao; Chie Kishigami; Shiho Nishimatsu; Yuki Sekine; Yoshikazu Inoue; David N McMurray; Mitsunori Sakatani
Journal:  Clin Dev Immunol       Date:  2011-03-07

Review 6.  Heat shock proteins: stimulators of innate and acquired immunity.

Authors:  Camilo A Colaco; Christopher R Bailey; K Barry Walker; James Keeble
Journal:  Biomed Res Int       Date:  2013-05-25       Impact factor: 3.411

7.  Innate signalling molecules as genetic adjuvants do not alter the efficacy of a DNA-based influenza A vaccine.

Authors:  Dennis Lapuente; Viktoria Stab; Michael Storcksdieck Genannt Bonsmann; Andre Maaske; Mario Köster; Han Xiao; Christina Ehrhardt; Matthias Tenbusch
Journal:  PLoS One       Date:  2020-04-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.